What we're reading, February 5, 2016: new legislation could expand the use of telehealth under Medicare; Massachusetts finds its physicians only screen for depression half the time; and Martin Shkreli pleads the Fifth during most of his testimony before Congress.
A senator from Hawaii has introduced legislation that would expand the use of telemedicine under Medicare and eliminate many of the current restrictions on reimbursement. Currently, to be reimbursed for telehealth under Medicare, patients must be located at certain sites in certain rural areas and only Medicare-defined physicians and practitioners can provide these services, according to Healthcare Informatics. The new legislation would expand the site for use and would make telehealth be a basic benefit in Medicare Advantage.
The US Preventive Services Task Force may now recommend that all adults are screened for depression, but there is a long way to go. The Boston Globe reported that in Massachusetts, primary care providers only ask patients if they are depressed or have other emotional problems just half the time. In comparison, these physicians earned much higher scores for screening patients who should be screened for colon cancer (81%) and screening diabetics for blood sugar problems (96%).
As probably should have been expected, during his testimony before members of Congress so-called “pharma bro” Martin Shkreli, the former CEO of Turing Pharmaceuticals, was of little help in the hearing. Shkreli mostly pled the Fifth and did not answer questions or smirked at comments from the members of the committee, STAT reported. After Shkreli, Turing’s chief commercial officer was more forthcoming with answers.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More